Evaxion Biotech (NASDAQ:EVAX) is flying high today as the company’s personalized cancer therapy EVX-01 reached an important milestone.
EVAX has now enrolled the first patient in the global Phase 2b trial of EVX-01which is being developed for the treatment of melanoma.
The trial is evaluating the efficacy and safety of the therapy in adults with metastatic melanoma.
Read full Disclosure